Coherus announces proposed public offering of common stock

Coherus Oncology, Inc. (NASDAQ: CHRS) announced a proposed underwritten public offering of its common stock. The company also intends to grant underwriters a 30-day option to purchase additional shares up to 15% of the shares offered, at the public offering price minus underwriting discounts and commissions.

The company plans to use net proceeds from the offering to support commercialization of LOQTORZI (toripalimab-tpzi), continue clinical development of product candidates, and for working capital and general corporate purposes.

TD Cowen, Guggenheim Securities, and Oppenheimer & Co. are serving as joint bookrunners for the proposed offering.

The offering is subject to market and other conditions, with no assurance regarding completion, timing, or final size and terms. The securities are being offered under an effective shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on November 13, 2025.

Coherus Oncology operates as a commercial-stage oncology company with LOQTORZI, an approved PD-1 inhibitor for recurrent or metastatic nasopharyngeal carcinoma. The company's pipeline includes tagmokitug, an anti-CCR8 antibody in Phase 1b/2a studies for advanced solid tumors, and casdozokitug, an IL-27 antagonistic antibody in Phase 2 evaluation for first-line hepatocellular carcinoma.

The information is based on a company press release statement.

You May Also Be Interested In

• Yarrow Bioscience prices $150M public offering at $26 per share
• TWO to repurchase $115M in senior notes after CrossCountry merger
• Tenable prices upsized $725M convertible notes offering